EG23791A - 1-(4-(1-4-Fluorophenyl-1H-indole-3-yl-1-butyl spiro (isobenzofuran 1-(3H), 4-Piperidine) hydrohalogenides - Google Patents

1-(4-(1-4-Fluorophenyl-1H-indole-3-yl-1-butyl spiro (isobenzofuran 1-(3H), 4-Piperidine) hydrohalogenides

Info

Publication number
EG23791A
EG23791A EG136298A EG136298A EG23791A EG 23791 A EG23791 A EG 23791A EG 136298 A EG136298 A EG 136298A EG 136298 A EG136298 A EG 136298A EG 23791 A EG23791 A EG 23791A
Authority
EG
Egypt
Prior art keywords
hydrohalogenides
isobenzofuran
fluorophenyl
indole
piperidine
Prior art date
Application number
EG136298A
Other languages
English (en)
Inventor
Niels Mork
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of EG23791A publication Critical patent/EG23791A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EG136298A 1997-11-07 1998-11-03 1-(4-(1-4-Fluorophenyl-1H-indole-3-yl-1-butyl spiro (isobenzofuran 1-(3H), 4-Piperidine) hydrohalogenides EG23791A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK126797 1997-11-07

Publications (1)

Publication Number Publication Date
EG23791A true EG23791A (en) 2007-08-13

Family

ID=8102935

Family Applications (1)

Application Number Title Priority Date Filing Date
EG136298A EG23791A (en) 1997-11-07 1998-11-03 1-(4-(1-4-Fluorophenyl-1H-indole-3-yl-1-butyl spiro (isobenzofuran 1-(3H), 4-Piperidine) hydrohalogenides

Country Status (39)

Country Link
US (2) US6844352B2 (ko)
EP (1) EP1044202B1 (ko)
JP (1) JP3605358B2 (ko)
KR (1) KR100399274B1 (ko)
CN (1) CN1105115C (ko)
AR (1) AR023010A1 (ko)
AT (1) ATE288918T1 (ko)
AU (1) AU749094B2 (ko)
BG (1) BG64906B1 (ko)
BR (1) BR9813949A (ko)
CA (1) CA2308745C (ko)
CZ (1) CZ288666B6 (ko)
DE (1) DE69828999T2 (ko)
DZ (1) DZ2642A1 (ko)
EA (1) EA002092B1 (ko)
EG (1) EG23791A (ko)
ES (1) ES2234162T3 (ko)
HK (1) HK1034075A1 (ko)
HR (1) HRP20000261B1 (ko)
HU (1) HUP0100991A3 (ko)
ID (1) ID25776A (ko)
IL (1) IL135723A (ko)
IS (1) IS2342B (ko)
JO (1) JO2052B1 (ko)
MA (1) MA25585A1 (ko)
NO (1) NO325920B1 (ko)
NZ (1) NZ504065A (ko)
PE (1) PE130299A1 (ko)
PL (1) PL190538B1 (ko)
PT (1) PT1044202E (ko)
RS (1) RS49777B (ko)
SK (1) SK285245B6 (ko)
TN (1) TNSN98201A1 (ko)
TR (1) TR200001267T2 (ko)
TW (1) TW483894B (ko)
UA (1) UA64769C2 (ko)
UY (1) UY25236A1 (ko)
WO (1) WO1999024436A1 (ko)
ZA (1) ZA9810116B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013789A1 (en) * 2000-08-15 2002-02-21 H. Lundbeck A/S Pharmaceutical composition containing 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl] -1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]
AU2003263155A1 (en) * 2002-09-20 2004-04-08 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
WO2004110389A2 (en) * 2003-06-12 2004-12-23 Agy Therapeutics, Inc. Sigma ligands for neuronal regeneration and functional recovery
DE112006002660A5 (de) * 2005-07-29 2008-07-10 Sigma-Aldrich Production Gmbh Ionisierungsadditive enthaltende LC/MS-Blends
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
BRPI0716604A2 (pt) * 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
IL135723A0 (en) 2001-05-20
EP1044202B1 (en) 2005-02-09
AU1022699A (en) 1999-05-31
ID25776A (id) 2000-11-02
TW483894B (en) 2002-04-21
TNSN98201A1 (fr) 2005-03-15
KR20010031791A (ko) 2001-04-16
TR200001267T2 (tr) 2000-09-21
EA200000502A1 (ru) 2000-10-30
ZA9810116B (en) 1999-05-07
UA64769C2 (uk) 2004-03-15
CA2308745A1 (en) 1999-05-20
HK1034075A1 (en) 2001-10-12
DZ2642A1 (fr) 2004-12-28
PE130299A1 (es) 1999-12-16
CZ20001663A3 (cs) 2000-10-11
PL190538B1 (pl) 2005-12-30
CN1105115C (zh) 2003-04-09
WO1999024436A1 (en) 1999-05-20
EP1044202A1 (en) 2000-10-18
KR100399274B1 (ko) 2003-09-26
IS5460A (is) 2000-04-18
AU749094B2 (en) 2002-06-20
NO20002188D0 (no) 2000-04-27
EA002092B1 (ru) 2001-12-24
HUP0100991A2 (hu) 2001-09-28
AR023010A1 (es) 2002-09-04
PL340220A1 (en) 2001-01-15
DE69828999D1 (de) 2005-03-17
RS49777B (sr) 2008-06-05
BR9813949A (pt) 2000-09-26
NZ504065A (en) 2002-05-31
SK285245B6 (sk) 2006-09-07
BG64906B1 (bg) 2006-08-31
CN1278823A (zh) 2001-01-03
DE69828999T2 (de) 2005-07-21
SK6462000A3 (en) 2000-10-09
IL135723A (en) 2005-11-20
NO20002188L (no) 2000-06-14
JP3605358B2 (ja) 2004-12-22
BG104485A (en) 2001-01-31
HRP20000261A2 (en) 2001-04-30
JP2001522852A (ja) 2001-11-20
JO2052B1 (en) 1999-05-15
ES2234162T3 (es) 2005-06-16
MA25585A1 (fr) 2002-12-31
PT1044202E (pt) 2005-04-29
HUP0100991A3 (en) 2003-03-28
HRP20000261B1 (en) 2009-04-30
CZ288666B6 (cs) 2001-08-15
ATE288918T1 (de) 2005-02-15
UY25236A1 (es) 2000-12-29
IS2342B (is) 2008-02-15
US20030055074A1 (en) 2003-03-20
US20050171135A1 (en) 2005-08-04
NO325920B1 (no) 2008-08-18
US6844352B2 (en) 2005-01-18
YU23500A (sh) 2003-12-31
CA2308745C (en) 2004-01-20

Similar Documents

Publication Publication Date Title
ZA9610885B (en) 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives.
ZA969090B (en) 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives.
EG25227A (en) Heterocyclic compounds.
ZA965935B (en) Heterocyclic compounds.
PL330042A1 (en) Novel 2,3-disubstituted 4(3h)-quinazolynones
ZA989767B (en) Novel compounds.
EG23791A (en) 1-(4-(1-4-Fluorophenyl-1H-indole-3-yl-1-butyl spiro (isobenzofuran 1-(3H), 4-Piperidine) hydrohalogenides
IL125177A0 (en) Novel benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
HU9600256D0 (en) Substituted diphenyl-sulfonamides, antagonists of endothelin
CY2271B1 (en) 1.(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
PL342732A1 (en) 1-(heteroarylpropyl- or -prop-2-enyl)-4 benzylpiperidine as antagopnists nmda receptor
ZA987055B (en) Substituted 4-benzoylpyrazoles.
DE59804842D1 (en) Aliphatische, emissionsarme, sinterfähige thermoplastische polyurethanformmassen
ZA987058B (en) Substituted 4-benzoylpyrazoles.
ZA982327B (en) Substituted 2-benz(O)ylpyridines.
ZA96702B (en) 4-(1H-indol-1-yl)-1-piperidinyl derivatives.
AU2517299A (en) Substituted alpha,beta-anellated butyrolactones
ZA200101830B (en) Piperidine derivatives.
ZA9811725B (en) Triazine compounds.
ZA9811758B (en) Novel compounds.
FI960616A0 (fi) 1-(2-(substituoitu-vinyyli))-3,4-dihydro-5H-2,3-bentsodiatsepiinijohdannaiset
ZA9811503B (en) Novel compounds.
ZA989826B (en) Peroxynitrate based bleaching systems.
ZA987B (en) Substituted 4-benzoylpyrazoles.
ZA98868B (en) Novel compounds.